Antitumor effects of cecropin B-LHRH’ on drug-resistant ovarian and endometrial cancer cells by Xiaoyong Li et al.
RESEARCH ARTICLE Open Access
Antitumor effects of cecropin B-LHRH’ on
drug-resistant ovarian and endometrial
cancer cells
Xiaoyong Li1, Bo Shen2, Qi Chen3, Xiaohui Zhang4, Yiqing Ye5, Fengmei Wang5 and Xinmei Zhang1*
Abstract
Background: Luteinizing hormone-releasing hormone receptor (LHRHr) represents a promising therapeutic target
for treating sex hormone-dependent tumors. We coupled cecropin B, an antimicrobial peptide, to LHRH’, a form of
LHRH modified at carboxyl-terminal residues 4–10, which binds to LHRHr without interfering with luteinizing
hormone (LH) and follicle-stimulating hormone (FSH) secretion. This study aimed to assess the antitumor effects of
cecropin B-LHRH’ (CB-LHRH’) in drug-resistant ovarian and endometrial cancers.
Methods: To evaluate the antitumor effects of CB-LHRH’, three drug resistant ovarian cancer cell lines (SKOV-3, ES-2,
NIH:OVCAR-3) and an endometrial cancer cell line (HEC-1A) were treated with CB-LHRH’. Cell morphology changes
were assessed using inverted and electron microscopes. In addition, cell growth and cell cytotoxicity were measured
by MTT assay and LDH release, respectively. In addition, hemolysis was measured. Furthermore, radioligand receptor
binding, hypersensitization and minimal inhibitory concentrations (against Staphylococcus aureus, Klebsiella pneumoniae,
Escherichia coli, Enterobacter cloacae, Pseudomonas aeruginosa, and Acinetobacter baumannii) were determined. Finally,
the impact on tumor growth in BALB/c-nu mice was assessed in an ES-2 xenograft model.
Results: CB-LHRH’ bound LHRHr with high-affinity (dissociation constant, Kd = 0.252 ± 0.061nM). Interestingly, CB-LHRH’
significantly inhibited the cell viability of SKOV-3, ES-2, NIH:OVCAR-3 and HEC-1A, but not that of normal eukaryotic
cells. CB-LHRH’ was active against bacteria at micromolar concentrations, and caused no hypersensitivity in guinea pigs.
Furthermore, CB-LHRH’ inhibited tumor growth with a 23.8 and 20.4 % reduction in tumor weight at 50 and 25 mg/
kg.d, respectively.
Conclusions: CB-LHRH’ is a candidate for targeted chemotherapy against ovarian and endometrial cancers.
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Background
Sex hormone-dependent tumors, including ovarian,
endometrial, breast and prostate carcinomas, are the
most common reproductive system tumors. Ovarian
cancer is often detected at a late stage [1–3]; despite
cytoreductive surgery and paclitaxel/platinum-based
chemotherapy it frequently recurs, resulting in poor
prognosis [4–6]. Although endometrial carcinoma
presents at an early stage and responds well to surgery
[7, 8], frequent recurrence also results in poor prognosis
[8, 9]. Chemotherapy of sex hormone-dependent cancers
is limited by the intrinsic or acquired drug resistance of
tumor cells as well as the toxicity to normal cells of
chemotherapeutic agents [5, 10, 11], whose side effect
profiles limit the chemotherapeutic dosing [12, 13].
Targeted cytotoxic agents enable selective treatment of
primary tumors and their metastases, reducing side ef-
fects and improving efficacy [2, 14–17]. Luteinizing
hormone-releasing hormone receptor (LHRHr) may rep-
resent a useful target in sex hormone-dependent tumors
as it is expressed in human breast (52 %), ovarian
(80 %), endometrial (80 %), and prostate (86 %) carcin-
omas [18]. Potential drawbacks of targeted chemother-
apy using natural LHRH as a binding partner include
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side effects resulting from interference with pituitary se-
cretion of LH and FSH [19]. Previous LHRHr targeted
cytotoxic therapies include cytotoxins, such as doxorubi-
cin, which have non-specific cytotoxicity. Other LHRHr
targeted therapies used chemical approaches linking the
cytotoxin to LHRH; however, such conjugates are readily
hydrolyzed in the blood stream, releasing cytotoxic radi-
cals before reaching their therapeutic targets, therefore
inducing non-specific cytotoxicity [19]. Refined and im-
proved strategies for LHRHr chemotherapy are neces-
sary if these approaches are to be useful.
LHRH is a decapeptide that binds to receptors on pituit-
ary gonadotropes, stimulating biosynthesis and secretion
of FSH and LH, which regulate gonadal steroidogenesis
and gametogenesis in both sexes [20]. The carboxyl-
terminal residues 4–10 of LHRH are involved in receptor
binding, while amino-terminal residues 1–3 activate the
receptors [21]. As targeted chemotherapy using natural
LHRH as a carrier may interfere with LH and FSH secre-
tion, we constructed a modified peptide, LHRH’, in which
amino-terminal residues 1–3 are not included. Thus,
LHRH’ is expected to target LHRHr positive carcinoma
cells, while not interfering with LH and FSH secretion.
Cecropin B is an antimicrobial peptide (AMP) first
characterized in 1980 [22, 23]; since then, thousands of
similar molecules have been isolated from a wide range
of organisms [24, 25]. AMPs are short peptides posses-
sing net cationic charges, selective toxicity, rapid cyto-
toxic effects, broad antimicrobial spectra, and no
documented resistance [24–26]. Some AMPs, including
cecropins, are highly potent against cancer cells but not
normal mammalian cells [27–31], making them attract-
ive for the treatment of some cancers.
In this study, we developed a novel LHRHr cytotoxin
by linking Cecropin B to the modified LHRH’ receptor
ligand, Cecropin B-LHRH’ (CB-LHRH’) [32]. We hy-
pothesized that the novel CB-LHRH’ may bind to LHRH
receptors and deliver an effective broad-spectrum toxin
specifically to tumor cells, without affecting healthy cells
or readily inducing resistance. Therefore, we aimed in
this study to assess the antitumor effects of CB-LHRH’
in the treatment of drug-resistant ovarian and endomet-
rial cancers, using BALB/c-nu mice (a common model
for cancer studies) harboring ES-2 xenografts.
Methods
The study was approved by the ethical committee of
Women’s Hospital, School of Medicine, Zhejiang University,
Hangzhou, China. Informed consent was obtained from all
individual participants included in the study.
Peptides and cytotoxic agents
CB-LHRH’ recombinant polypeptide (KWKVFKKIEKM
GRNIRNGIVKAGPAIAVLGEAKALSYGLRPG) (Shanghai
Sangon Biological Engineering Technology & Services
Corporation, Shanghai, China) was synthesized by solid
phase synthesis to a purity of 96 % as evaluated by high-
performance liquid chromatography. It was identified by
mass spectrographic analysis (MW 4,566.57D), dissolved
in phosphate-buffered saline (PBS), and diluted to the de-
sired concentration before use.
Drug-resistant tumor cell lines
Four drug-resistant cancer cell lines, including three
ovarian cancer cell lines (SKOV-3, ES-2, NIH:OVCAR-
3) and one endometrial cancer cell line (HEC-1A) (Cell
Bank of Shanghai Biological Institute, Shanghai, China),
were cultured in RPMI 1640 with 10 % fetal bovine
serum, 1,000 IU/mL penicillin, and 100 mg/mL strepto-
mycin at 37 °C and 5 % CO2. Cell cultures and subcul-
ture procedures were performed according to the
recommendations of the ATCC Global Bioresource
Center. ES-2, HEC-1A, and NIH:OVCAR-3 cells ex-
press LHRHr, while the SKOV-3 does not express
LHRHr [33–35].
Clonogenic assay
A clonogenic assay was carried out as previously de-
scribed [36]. 300 cells were seeded into 6-well dishes in
2 mL of medium. After overnight incubation, CB-LHRH’
was added at a final concentration of 12.5 μM and cells
were further cultured for 10 d. Cells were then stained
with crystal violet (0.5 % w/v). Colonies containing a
minimum of 50 cells were counted using a dissection
microscope. Each treatment was performed in triplicate
and each experiment repeated three times.
Cytotoxicity assay
Lactate dehydrogenase (LDH) release was quantified
using LDH Cytotoxicity Detection Kit (Roche Applied
Science, Mannheim, Germany) according to the manu-
facturer’s instructions. Briefly, 100 μL of exponentially
growing tumor cells (6 × 104 cells/mL) were seeded into
96-well plates, cultured overnight, and washed with
RPMI 1640. Then, several CB-LHRH’ amounts (6.25,
12.5, 25, 50, and 100 μM) were completed to 100 μL
with RPMI and added to cells, followed by 4 h incuba-
tion. LDH release was assessed by measuring absorbance
at 490 and 630 nm, respectively, on a microplate reader
(Bio-Tek Instruments Inc., Vermont, USA). Cytotoxicity
was determined by the following formula: Cytotoxicity
(%) = (exp. value - low control)/(high control - low con-
trol) x 100. All conditions were carried out in triplicate,
and the experiments repeated three times.
Proliferation assay
The anti-proliferative activity of CB-LHRH’ was assessed
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
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bromide (MTT) assay [37]. Briefly, 100 μL of exponentially
growing tumor cells (6 × 104 cells/mL) were seeded in 96-
well plates and cultured overnight. B-LHRH’ was then
added to each well at final concentrations of 6.25, 12.5, 25,
50, and 100 μM. After another 24 or 48 h, 10 μL of fresh
MTT (Sigma–Aldrich, St. Louis, USA) at 5 mg/mL in
Hank’s salt solution was added for 4 h. After careful
removal of the medium, 100 μL dimethylsulfoxide (Sigma–
Aldrich, St. Louis, USA) was added to wells followed by
absorbance reading on a microplate reader (Bio-Tek
Instruments Inc, Vermont, USA) at 490 and 630 nm,
respectively. Cell viability was determined as follows:
Cell viability (%) = (absorbance of treated wells - absorb-
ance of blank control)/(absorbance of negative control -
absorbance of blank control) x 100. The inhibition rate
was derived as 1-Cell viability. Each experiment was per-
formed in triplicate and repeated three times.
Cell morphology was monitored using inverted and
electron microscopes after 1 h exposure to CB-LHRH’ as
previously described [38].
Electron microscopy
For transmission electron microscopy ES-2 cells grown on
sterile slides were fixed with 2.5 % glutaraldehyde in
pH 7.4 phosphate buffer for 1 h at 4 °C, followed by post-
fixation in 1 % osmium tetroxide 1 h at 4 °C and dehy-
drated in an alcohol gradient (50 to 100 %). The attached
cells were then dried by Lyophilization and coated with
Au before examination with transmission electron micro-
scope (S-4800 SEM, Hitachi, Ltd. Tokyo, Japan).
For scanning electron microscopy ES-2 cells were grown
and fixed under similar conditions, without slides. After
post-fixation cells were infiltrated with Epon resin and
sectioned with Leica UC6 ultramicrotome (Leica Micro-
systems Inc., LKB-II, Wetzlar, Germany). Sections of about
100 nm were post-stained with lead citrate and uranyl
acetate. Grids were examined with scanning electron
microscope (JEM-200CX TEM, JEOL, Ltd. Tokyo, Japan).
Cytotoxicity of CB-LHRH’ in normal eukaryotic cells
The ability of CB-LHRH’ to induce cytotoxicity in nor-
mal eukaryotic cells was assessed as previously described
[39]. With informed consent and institutional review
board approval, peripheral blood samples were obtained
from healthy human donors. Red blood cells were sepa-
rated by centrifugation at 1,000 g for 5 min followed by
three washes with PBS. Washed red blood cells were re-
suspended in sterile Alsever’s solution (2.05 % dextrose,
0.8 % sodium citrate, 0.055 % citric acid, and 0.42 % so-
dium chloride, pH 6.1, hematocrit 5 %) in a plate and
treated with CB-LHRH’ at 100, 200, 300, 400, or 500 μM
for either 30 min or 4 h at 37 °C with shaking. After cen-
trifugation for 10 min at 600 g, the supernatant was col-
lected for hemolysis measurement at 490 nm (hemoglobin
absorbance). Adding equal volumes of water to red blood
cells provided 100 % hemolysis (positive control); cell-
free Alsever’s solution was used as negative control.
Each experiment was performed in triplicate and re-
peated three times.
Radioligand receptor binding assays
Under approved animal research protocol standards,
binding capacity to LHRHr was assessed in rat pituitary
membranes by radioligand-binding assays as previously
described [40]. The experiment was approved by the ani-
mal care and use committee of Fudan University.
Preparation of membrane fractions for primary pituicytes
To obtain primary pituicytes, SD male and female rats
(180–240 g) were sacrificed and the pituitary glands dis-
sected and washed twice with 10 mM Tris-HCl buffer,
pH 7.4, containing 0.5 mM PMSF, 1.2 mM MgCl2,
0.01 mM EDTA-Na2. Tissue aliquots were homogenized
using an automatic glass Potter homogenizer at 2000 rpm
for 3 × 10 s. After nucleus and debris removal by centrifu-
gation at 2000 g and 4 °C for 5 min, membrane prepar-
ation aliquots were collected by centrifugation at 2000 g
and 4 °C for 20 min. Protein concentrations were deter-
mined by the Lowry method using bovine serum albumin
(BSA) as a standard, diluted with 10 mM Tris-HCl buffer
to 2 mg/mL stock at −70 °C.
Radioligand receptor binding assay
CB-LHRH’ peptide was radioactively labeled with Iodine-
125 (Perkin Elmer Life and Analytical Sciences, Waltham,
USA) using Chloramine-T (Sigma–Aldrich, St. Louis,
USA) and purified on Sephadex G15 chromatography
(Sigma–Aldrich) using 0.1 mM aqueous acetic acid, con-
taining 2.5 g/L BSA as eluent. The specific activity of 125I-
CB-LHRH’ was about 0.2 ~ 0.24 mCi/mmol with a purity
greater than 95 %. In the binding assay, polypropylene
tubes were pretreated overnight at 4 °C with 10 mM Tris-
HCl, pH 7.4 containing 1 % BSA. Membrane fraction ali-
quots (100 μg protein in 50 μL per tube) were incubated
with different concentrations of 125I-CB-LHRH’ at 37 °C
for 1 h in a total volume of 150 μL. To examine the bind-
ing specificity, 2 μg gonadorelin (Tash Biotechnology,
Shanghai, China) was used as competitor. Reactions were
terminated by adding 1 mL of 10 mM Tris-HCl buffer
(pH 7.4, 4 °C). The solutions were subsequently filtered
onto Whatman filters, washed with 1 mL of 5 %
trichloroacetic acid and transferred to a counting tube.
The radioactivity was measured by a gamma counter
(GC-300, AnHui ustc ZonKia Scientific Instruments co.
LTD, Hefei, China). Specific binding was determined by
subtracting nonspecific from total binding. The equilib-
rium dissociation constant (Kd) and maximum binding
capacity (Bmax) were derived by the Scatchard method.
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Kd represents the concentration of drug inducing the
half (50 %) biggest effect. Bmax indicates the maximum
binding volume combined per mg receptor proteins.
Each experiment was performed in triplicate and re-
peated three times.
Hypersensitization test
Under approved animal research protocol standards, the
hypersensitive reaction against CB-LHRH’ (2 mg/mL, equal
to 438 μM) was assessed in guinea pigs. According to the
Chinese Pharmacopoeia, six animals with an average weight
of 250 g (XiFengYang Special Economic Animal Farm,
Huzhou, China) were administered an intraperitoneal injec-
tion of 0.5 mL of CB-LHRH’ every other day three times,
while three additional animals received PBS physiological
saline injections. Of the six animals administered CB-
LHRH’, three received an intravenous injection of 1 mL
CB-LHRH’ at day 15, and the remaining three at day 22. Al-
lergic reactions, such as piloerection, sneezing, lacrimation,
dyspnoea, and hyperspasmia, were then monitored for the
next 30 min.
Antibacterial assay
The antibacterial activity of CB-LHRH’ was evaluated by
the agar dilution method [41]. Muller Hinton’s agar
medium plates containing serial dilutions of CB-LHRH’
were inoculated with 2 μL of tenfold-diluted 0.5 McF
bacteria and incubated for 22 h at 35 °C. The lowest
concentration of CB-LHRH’ inhibiting bacterial growth
was considered the minimal inhibitory concentration
(MIC). Nine clinical strains of the following species were
evaluated: Staphylococcus aureus, Klebsiella pneumo-
niae, Escherichia coli, Enterobacter cloacae, Pseudo-
monas aeruginosa, and Acinetobacter baumannii.
Xenograft studies
Five- to six-week-old female (15–20 g) athymic nude
mice (BALB/c-nu) were obtained from Shanghai SLAC
Laboratory Animal Corporation, China. The animals
were housed in sterile cages under laminar flow hoods
in a temperature controlled room with a 12-hour light/
12-hour dark cycle, and fed autoclaved chow and water
ad libitum. All experiments were carried out in accord-
ance with the guidelines for the welfare ethics of experi-
mental animals [42]. All the animal-related procedures
were approved by the Animal Ethical Committee of
Zhejiang University.
Experimental protocol
Cultured ES-2 ovarian cancer cells were resuspended at
1 × 107/ml and inoculated subcutaneously into the nude
mouse armpit. When tumors reached 60 mm3, they were
extracted, cut into pieces of about 2 mm3, and inocu-
lated subcutaneously into the nude mouse armpit. When
the tumors reached an average volume of about
100 mm3, the mice were randomly divided into five
groups (n = 10). Groups 1–3 received intra-tumor injec-
tion of CB-LHRH’ twice daily at 12.5, 25 or 50 mg/kg.d,
respectively. Group 4 received 2 mg/kg cisplatin, once
every 3 days [43], and group 5 the same volume of PBS,
administered twice daily.
Tumor volumes were assessed every 3 d as 0.5 ×
length × width2 (where length is the longest diameter
across the tumor and width the corresponding perpen-
dicular diameter as measured by calipers). On day 13,
4 h after the last dose, mice were sacrificed, and tumors
excised and weighed; tumor growth inhibition rate was
derived as (1-tumor weight treated/tumor weight con-
trol) × 100 %.
Response criteria
Anti-tumor activity was evaluated as relative growth of
tumor volume (T/C, value), the mean relative tumor
volume (RTV) for the treatment group divided by the
mean RTV for the control group, as follows: T/C (%) =
TRTV/CRTV X 100 %. RTV = Vt/V0, where Vt is the vol-
ume on any given day, and V0 the volume at treatment
start. Agents producing a T/C of >60 % were considered
to be inactive, those with a mean T/C of ≤60 % consid-
ered to be active.
General toxicity was evaluated based on body weight,
measured weekly.
Statistical analysis
Data are mean ± standard deviation (SD). Normality and
homogeneity of variance assumptions were assessed.
One way analysis of variance (ANOVA) was used for
multiple group comparison, as required. SPSS 16.0
(SPSS, USA) was used for the statistical analysis. p < 0.05
was considered statistically significant.
Results
CB-LHRH’ inhibited proliferation of cancer cell lines
Three drug-resistant ovarian cancer cell lines (SKOV-3,
ES-2, NIH:OVCAR-3) and one drug-resistant endomet-
rial cancer cell line (HEC-1A) were incubated with
12.5 μM CB-LHRH’. After 10 d there were almost no
colonies after CB-LHRH’ treatment, while control wells
contained approximately 30–50 colonies, indicating that
12.5 μM CB-LHRH’ significantly inhibited the growth of
drug-resistant cancer cells.
Damage to all four cell lines was observed within 24 h
of exposure to 12.5 μM CB-LHRH’ by light microscopy
(data not shown). And the effect of CB-LHRH’ on ES-2
cell morphology was shown in Fig. 1. Typical cell dam-
age included aggregation, detachment from the plate, in-
flation, cytoplasm leak, disintegration into granules, and
decreased cell number (Fig. 1).
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Electron microscopy revealed cell membrane blebbing,
the disappearance or reduction of microvilli, cell shrink-
age, increased cellular granularity, the formation and
separation of apoptotic bodies, and cytoplasm leak in re-
sponse to 25 μM CB-LHRH’ in ES-2 cell (Fig. 2).
All four cell lines incubated for 4 h with CB-LHRH’ ex-
hibited concentration-dependent cytotoxicity (P < 0.001)
as shown in Fig. 3. And there were no differences among
the four cell lines (Fig. 3). In contrast, CB-LHRH’ caused
no hemolysis of red blood cells from healthy human do-
nors (data not shown).
Proliferation of all four drug-resistant cancer cell lines
was inhibited by CB-LHRH’ in a concentration-dependent
manner (P < 0.001) (Fig. 4a–d). And the greatest inhibition
Fig. 1 Cecropin B-LHRH’ induces changes in ES-2 morphology. Untreated cells (a–c, 10, 20, and 40×, respectively), display normal morphology,
while cells treated with 25 μM cecropin B-LHRH’ for 24 h (d–f, 10, 20, and 40×, respectively) showed reduced number, and aggregated, detached
from the plate, inflated, released cytoplasm, and disintegrated into granules. Morphological changes observed in ES-2 cell line
Fig. 2 Cecropin B-LHRH’ induces ultrastructural changes in ES-2 cells. Transmission electron microscope images (a–e), and scanning electron
microscope images (f) of a normal ES-2 cell (a); ES-2 cells incubated with 25 μM cecropin B-LHRH’ for 1 h (b–f). Figures b–d illustrate cell
membrane blebbing, the disappearance or reduction of microvilli, cell shrinkage, increased cellular granularity, and the formation and separation
of apoptotic bodies. e and f show cytoplasm leak. Morphological changes observed in ES-2 cell line
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was obtained for ES-2 cells, and CB-LHRH’ inhibited cell
proliferation in ES-2 cell in a time-dependent manner (P
< 0.05) (Fig. 4c). Inhibition of SKOV-3 and HEC-1A cell
proliferation was weaker at the dose of lower than 25 μM
and 50 μM, respectively (Fig. 4a and 4b). And inhibition of
NIH:OVCAR-3 cell proliferation was up to 40 % even at
the high dose of 100 μM (Fig. 4d).
CB-LHRH’ is a high-affinity ligand for LHRHr
The binding affinity of CB-LHRH’ to the LHRH receptor
was assessed in rat pituitary membranes by radioligand-
binding assays. Kd and Bmax values were 0.2526 ± 0.061
nM and 110.4 ± 17.68 fmol/mg protein, respectively
(Fig. 5), indicating that 125I-CB-LHRH’ is a high-affinity
ligand for LHRHr.
CB-LHRH’ does not induce hypersensitivity
The potential of CB-LHRH’ to induce a hypersensitive
reaction in mammals was assessed in the guinea pig
model. Guinea pigs administered 0.5 mL 2 mg/ml CB-
LHRH’ intraperitoneally every other day three times
(n = 6) survived the 15 days of treatment and their
weights did not differ significantly from animals ad-
ministered PBS (n = 3). Afterwards, three animals were
administrated an additional 1 mL of 2 mg/ml CB-
LHRH’. No anaphylaxis occurred in any of the six
guinea pigs treated with CB-LHRH’ (data not shown).
CB-LHRH’ inhibits Gram-negative bacteria
The antibacterial activity of CB-LHRH’ was evaluated by
the agar dilution method. CB-LHRH’ killed or inhibited
the growth of all tested gram-negative bacteria at micro-
molar concentrations. The minimal inhibitory concentra-
tions (MIC) were 1.93–7.72 μM, 3.86–7.72 μM, 3.86–
Fig. 3 Cytotoxicity of cecropin B-LHRH’ against the four cancer cell
lines. Cytotoxicity was detected in SKOV-3, ES-2, NIH:OVCAR-3, and
HEC-1A cells incubated overnight with CB-LHRH’ by LDH Cytotoxicity
Detection Kit. Concentration-dependent cytotoxicity was observed in
all four cell lines
Fig. 4 Cecropin B-LHRH’ inhibition of cancer cell proliferation. Proliferation inhibition was detected in (a) SKOV-3, (b) HEC-1A, (c) ES-2 and (d)
NIH:OVCAR-3 cells incubated with CB-LHRH’ at the dose of 6.25 μM, 12.5 μM,25 μM,50 μM, and 100 μM for 24 h or 48 h by the MTT assay.
Proliferation was inhibited in a time- and concentration-dependent manner in ES-2 cell line (p = 0.026), and in a concentration-dependent manner
in other three cell lines (p < 0.001 vs 6.25 μM). Data are presented as mean ± SD, n = 3
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7.72 μM, 3.86–7.72 μM, ≥15.44 μM, and >15.44 μM for
Acinetobacter baumannii, Escherichia coli, Enterobacter
cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa,
and Staphylococcus aureus, respectively (Table 1).
CB-LHRH’ inhibits ES-2 Xenograft growth in vivo
Nude mice were implanted with ES-2 and adminis-
tered intra-tumoral injection of CB-LHRH’ twice daily
at 0, 12.5, 25 or 50 mg/kg.d, or 2 mg/kg cisplatin,
once every 3 days (n = 10); thirteen days later 9, 8, 9,
7 and 8 surviving mice were obtained, respectively
(Tables 2 and 3).
However, administration of CB-LHRH’ at 50 and
25 mg/kg significantly inhibited the growth of ES-2 Xe-
nografts by day 13, resulting in tumor sizes of 50 % and
59 % the control values (P < 0.01), and 23.8 % and
20.4 % decrease in tumor weights (P < 0.05), respect-
ively; no differences were found in animal weights.
Discussion
In this study, we developed a novel LHRHr cytotoxin
strategy by linking Cecropin B to the modified LHRH’
receptor ligand in order to deliver an effective broad-
spectrum toxin specifically to tumor cell targets, without
affecting gonadotrophin secretion in healthy cells or in-
ducing resistance.
CB-LHRH’ binds to LHRHr with a low dissociation
constant of 0.252 ± 0.061 nM, indicating the high-affinity
of the modified peptide, which should have broad-
spectrum toxicity against cancer cells expressing LHRHr.
Indeed, CB-LHRH’ was cytotoxic to ES-2 and NIH:OV-
CAR-3 (ovarian cancer cells) and HEC-1A (endometrial
cancer cells) which express LHRHr, while displaying the
weakest cytotoxicity in the LHRHr negative ovarian can-
cer cell line SKOV-3. Of note, the four cancer cell lines
sensitive to CB-LHRH’ are known to be resistant to
several cytotoxic drugs, including diphtheria toxin,
doxorubicin, cisplatin, and adriamycin, among others,
according to the ATCC Global Bioresource Center
(USA). For instance, ES-2 cells were derived from an
ovarian clear cell carcinoma characterized by unique
clinical features such as high incidence in stage I of the
disease, relatively strong resistance to conventional plat-
inum or taxane-based chemotherapies, and poor prog-
noses [44–46]. The overt cytotoxicity demonstrated for
CB-LHRH’ against several multidrug-resistant cancer
cell-lines, particularly ES-2 cells, indicates that the new
peptide might help in the treatment of some cancers re-
sistant to currently available chemotherapeutics; indeed,
CB-LHRH’ is a promising candidate for the treatment of
LHRHr dependent cancers.
Fig. 5 Saturation curve and Scatchard plot of LHRHr-specific 125I-cecropin B-LHRH’ binding. The binding affinity of CB-LHRH’ to the LHRH receptor
was assessed in rat pituitary membranes by radioligand-binding assays. TB, total binding; SB, specific binding; NSB, non-specific binding. Each
experiment was performed in triplicate and repeated three times
Table 1 The MIC of the Cecropin B-LHRH’ against the six kinds






Pseudomonas aeruginosa > = 15.44
Staphylococcus aureus >15.44
Table 2 Therapeutic effect of Cecropin B-LHRH’ on the volume
of ES-2 tumors xenografted into nude mice (Mean ± SD)
Group Dose
(mg/kg.d)
Tumor Volume (mm3) RTV T/C
(%)d 1 d 13
CB-LHRH’ 50 308.91 + 110.19 965.92 + 212.31** 3.13 50
25 364.18 + 112.16 1334.78 + 179.25** 3.67 59
12.5 298.23 + 107.54 1416.71 + 353.71** 4.75 76
Cisplatin 0.67 343.91 + 123.06 913.16 + 142.64** 2.66 42
PBS 326.56 + 85.00 2042.62 + 239.07 6.5 –
In comparison to the PBS control, ** P < 0.01
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The mechanisms underlying the antimicrobial and
anticancer effects of cecropin include plasma mem-
brane disruption via micellization, or pore formation by
peptide-lipid interactions [47, 48]. Cationic peptides
target characteristic, cell-surface, anionic lipids by elec-
trostatic attraction that are ubiquitous and exclusive to
micro-organisms, followed by membrane permeation
and disruption. This simple electrostatic discrimination
provides selective toxicity, as well as a broad spectrum
of antimicrobial activity. Unspecific molecular recogni-
tion makes the development of resistance difficult.
Eukaryotic cell membranes have important amounts of
sterols, and the membrane-stabilizing cholesterol pro-
tects normal eukaryotic cells from attacks by thera-
peutic peptides [47, 48]. Changes in lipid compositions
of cancer cell membranes may be a reason why these
peptides show specific toxicity to cancer cells [30]. In
this study, loss of cytoplasm and disintegration of
cancer cells, with no hemolytic activity in normal red
blood cells, supports similar anticancer mechanisms of
plasma membrane disruption.
CB-LHRH’ also induced no hypersensitive reactions
in guinea pigs, suggesting that CB-LHRH’ may not
cause severe allergy, a common problem of peptide
drugs. This benign profile distinguishes the newly de-
veloped polypeptide from other chemotherapeutics, as
the safety of chemotherapeutics is one of the most
important features of contemporary drug treatment.
However, these results need to be replicated in hu-
man subjects in order to rule out potential relevant
inter-species differences. In addition, the anticancer
effects of CB-LHRH’ was assessed after intra-tumoral
administration, which does not fully recapitulate the
targeting of tumors in the peritoneal space.
CB-LHRH’ also inhibited the growth of clinically iso-
lated bacteria at micromolar concentrations, indicating
a potent antibacterial effect. The antibacterial and anti-
cancer functions of CB-LHRH’ suggest that the
carboxyl-terminal extension of CB doesn’t alter its anti-
bacterial properties. In addition to inhibiting growth of
cancer cells, CB-LHRH’ may also benefit cancer
patients with its antibacterial function, since bacterial
infections are a major cause of morbidity and mortality
in neutropenic patients following chemotherapy for
malignancy [49].
Conclusion
LHRH’ may represent a more promising therapeutic
than LHRH, and cecropin B appears to be a potentially
valuable component of targeted therapies. The peptide
drug CB-LHRH’ described here is a potent candidate for
cancer therapy, with broad anti-cancer spectrum and
minimal toxicity to normal eukaryotic cells.
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Table 3 Therapeutic effects of Cecropin B-LHRH’ on the weight
of ES-2 tumors xenografted into nude mice (Mean ± SD)
Group Tumor Weight (g) Tumor growth
inhibition rate (%)
50 mg/kg.d CB-LHRH’ 1.31 ± 0.31* 23.8
25 mg/kg.d CB-LHRH’ 1.37 ± 0.15* 20.4
12.5 mg/kg.d CB-LHRH’ 1.40 ± 0.81 18.4
Cisplatin 1.09 ± 0.25 ** 36.4
PBS 1.72 ± 0.24 -
In comparison to the PBS control, *P < 0.05; **P < 0.01
Each experiment was performed in triplicate and repeated three times
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